Drug intelligence / Profile preview

HD6610

Development stage: Phase 3
Lead developer: Jiangsu Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

HD6610 is an oral granule formulation of **Jiawei Huangqi Guizhi Wuwu Tang**, a traditional multi-herb Chinese medicine formula. It was evaluated as supportive treatment for **oxaliplatin-induced peripheral neuropathy** in patients with colorectal cancer receiving oxaliplatin-based chemotherapy, in a randomized, double-blind, placebo-controlled Phase 2/3 study sponsored by Jiangsu Province Hospital of Traditional Chinese Medicine. Its specific molecular targets and pharmacological mechanism have not been publicly established. ([figshare.com](https://figshare.com/articles/figure/HD6610_granules_relieve_oxaliplatin-induced_peripheral_neuropathy_study_protocol_for_a_multicenter_randomized_double-blind_placebo-controlled_trial/3406555))

Other names: Jiawei Huangqi Guizhi Wuwu Tang

Beyond the preview

Go deeper on HD6610.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD6610.

Explore the full profile